Company Press Release
SOURCE: Creative BioMolecules, Inc.
Creative Biomolecules and The University of Colorado School of Medicine
Receive Grant From NIH For Parkinson's Research
HOPKINTON, Mass., Oct. 6, 1998 /PRNewswire/ -- Creative BioMolecules,
Inc. announced today that it has received a Phase I Small Business
Innovation Research (SBIR) grant from the National Institutes of
Health (NIH) for research into morphogenic protein-based therapies for
the treatment of Parkinson's Disease. The research is being conducted in
collaboration with Paula C. Bickford, Ph.D., Associate Professor of
Pharmacology at the University of Colorado's School of Medicine.
Creative BioMolecules has proprietary rights to a family of neurotrophic
proteins with demonstrated activity in multiple animal models of disease
including stroke and initial results in Parkinson's Disease. This grant
will support research to evaluate the potential of these proteins to
restore dopaminergic neurons, the brain cells damaged in
Parkinson's Disease, and promote the reestablishment of signaling
pathways in the central nervous system.
Dr. Bickford commented, ``Factors that promote the survival or prevent
the progressive deterioration of dopaminergic neurons may have
significant benefit in treating Parkinson's Disease. Early research
indicates that OP-1 may represent the first protein in an exciting
family of neurotrophic factors.''
--
Judith Richards, London, Ontario, Canada
<[log in to unmask]>
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
```````
